In HNSCC cells, co-treatment of PD0325901 with the PI3K/mTOR inhibitor PF-384 overcame resistance by blocking ERK signaling and enhanced anti-proliferative, pro-apoptotic, and anti-angiogenic effects in vitro and in vivo [15]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.